Complete Genomics Inc Quick Ratio (GNOM) starting from the third quarter 2012 to third quarter 2011, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Complete Genomics Inc  (GNOM)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Complete Genomics Inc's Quick Ratio

GNOM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2012, Quick Ratio fell to 0.76 a new company low.

Within Medical Laboratories industry 11 other companies have achieved higher Quick Ratio than Complete Genomics Inc in third quarter 2012. While Quick Ratio total ranking has improved so far during the Q3 2012 to 1522, from total ranking in the second quarter 2012 at 1755.

Explain Quick Ratio?
How much Cash & cash equivalents GNOM´s has?
What are GNOM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNOM Quick Ratio (Sep 30 2012)
Q3		 (Jun 30 2012)
Q2		 (Mar 31 2012)
Q1		 (Dec 31 2011)
Q4		 (Sep 30 2011)
Q3
Y / Y Current Liabilities Change 102.82 % 108.01 % 157.25 % - -
Y / Y Cash & cash equivalent Change -66.97 % -65.78 % -8.42 % - -
Quick Ratio MRQ 0.76 0.99 1.39 2.98 4.69
GNOM's Total Ranking # 1522 # 1755 # 1755 # 1752 #
Seq. Current Liabilities Change 4.09 % -3.98 % 63.15 % 24.37 % 6.76 %
Seq. Cash & cash equivalent Change -19.75 % -31.46 % -24.02 % -20.97 % -16.85 %



Quick Ratio third quarter 2012 Company Ranking
Within: No.
Medical Laboratories Industry # 12
Healthcare Sector # 298
Overall Market # 1522


Quick Ratio Statistics
High Average Low
2.98 1.53 0.76
(Dec 31 2011)   (Sep 30 2012)




Financial Statements
Complete Genomics Inc's Current Liabilities $ 45 Millions Visit GNOM's Balance sheet
Complete Genomics Inc's Cash & cash equivalent $ 35 Millions Visit GNOM's Balance sheet
Source of GNOM's Sales Visit GNOM's Sales by Geography


Cumulative Complete Genomics Inc's Quick Ratio

GNOM's Quick Ratio for the trailling 12 Months

GNOM Quick Ratio

 (Sep 30 2012)
12 Months		 (Jun 30 2012)
12 Months		 (Mar 31 2012)
12 Months		 (Dec 31 2011)
12 Months		 (Sep 30 2011)
12 Months
Y / Y Current Liabilities TTM Growth 165.99 % 260.55 % 560.46 % - -
Y / Y Cash & cash equivalent TTM Growth -25.39 % 50.8 % 448.07 % - -
Quick Ratio TTM 1.38 2.11 3.23 4.31 4.92
Total Ranking TTM # 1043 # 0 # 0 # 0 #
Seq. Current Liabilities TTM Growth 16.53 % 19.42 % 31.25 % 45.63 % 57.95 %
Seq. Cash & cash equivalent TTM Growth -23.9 % -22.02 % -1.51 % 27.65 % 53.81 %

Quick ratio ranking by company, industry and sector >> Back to GNOM Financial Strength Comparisons >> Go to Compare GNOM Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2012 to $45.48 millions, cumulative Quick Ratio decreased to 1.38 below the Complete Genomics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 6 other companies have achieved higher Quick Ratio than Complete Genomics Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2012 from 0 to 1043.

Explain Quick Ratio?
How much Cash & cash equivalents GNOM´s has?
What are GNOM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 7
Healthcare Sector # 83
Within the Market # 1043


trailing twelve months Quick Ratio Statistics
High Average Low
1.38 1.38 1.38
(Sep 30 2012)  




Companies with similar Quick Ratio in the quarter ending Sep 30 2012, within Medical Laboratories Industry Quick RatioSep 30 2012 MRQ Cash & cash equivalentSep 30 2012 MRQ Current Liabilities
Incyte Corporation  1.84 $ 253.099  Millions$ 137.641  Millions
Dyax Corp  1.76 $ 30.389  Millions$ 17.291  Millions
Nuo Therapeutics, Inc.  1.63 $ 5.886  Millions$ 3.612  Millions
Psychemedics Corporation  1.63 $ 3.663  Millions$ 2.251  Millions
Icon Plc  0.90 $ 179.913  Millions$ 200.853  Millions
Hologic Inc  0.86 $ 566.126  Millions$ 661.349  Millions
American Shared Hospital Services  0.85 $ 9.050  Millions$ 10.697  Millions
Luna Innovations Inc  0.83 $ 6.722  Millions$ 8.067  Millions
Complete Genomics Inc  0.76 $ 34.715  Millions$ 45.479  Millions
Biocept Inc   0.57 $ 13.184  Millions$ 23.265  Millions
Aeon Global Health Corp.  0.53 $ 3.908  Millions$ 7.441  Millions
Labcorp Holdings Inc   0.42 $ 466.000  Millions$ 1,119.400  Millions
Nrc Health  0.40 $ 15.026  Millions$ 37.687  Millions
Icagen, Inc.  0.28 $ 0.196  Millions$ 0.688  Millions
Charles River Laboratories International inc   0.26 $ 83.224  Millions$ 325.237  Millions
Evolutionary Genomics Inc   0.25 $ 0.000  Millions$ 0.000  Millions
Quest Diagnostics Inc  0.18 $ 191.770  Millions$ 1,070.640  Millions

Date modified: 2026-09-08T15:07:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.